NMR
Overvalued by 163.8% based on the discounted cash flow analysis.
Market cap | $17.74 Billion |
---|---|
Enterprise Value | $9.85 Trillion |
Dividend Yield | $0.25 (3.76669329985162%) |
Earnings per Share | $52.69 |
Beta | 0.55 |
Outstanding Shares | 2,955,740,093 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 7.6 |
---|---|
PEG | 4.24 |
Price to Sales | 0.01 |
Price to Book Ratio | 0.0 |
Enterprise Value to Revenue | 3.09 |
Enterprise Value to EBIT | 26.94 |
Enterprise Value to Net Income | 35 |
Total Debt to Enterprise | 1.56 |
Debt to Equity | 4.32 |
No data
No data